Compare BML, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 146,087 Million (Small Cap)
19.00
NA
0.00%
-0.51
6.39%
1.14
Revenue and Profits:
Net Sales:
39,036 Million
(Quarterly Results - Jun 2026)
Net Profit:
2,060 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.54%
0%
-6.54%
6 Months
-11.62%
0%
-11.62%
1 Year
2.73%
0%
2.73%
2 Years
30.62%
0%
30.62%
3 Years
23.28%
0%
23.28%
4 Years
-8.92%
0%
-8.92%
5 Years
-13.12%
0%
-13.12%
BML, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.40%
EBIT Growth (5y)
-5.14%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.50
Sales to Capital Employed (avg)
1.12
Tax Ratio
33.18%
Dividend Payout Ratio
61.42%
Pledged Shares
0
Institutional Holding
0.05%
ROCE (avg)
59.47%
ROE (avg)
13.86%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
1.18
EV to EBIT
8.06
EV to EBITDA
4.34
EV to Capital Employed
1.37
EV to Sales
0.56
PEG Ratio
0.60
Dividend Yield
NA
ROCE (Latest)
16.98%
ROE (Latest)
6.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2022
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.05%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
39,036.00
35,787.00
9.08%
Operating Profit (PBDIT) excl Other Income
5,246.00
3,775.00
38.97%
Interest
31.00
30.00
3.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
2,060.00
1,249.00
64.93%
Operating Profit Margin (Excl OI)
76.90%
34.10%
4.28%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 9.08% vs -7.88% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 64.93% vs -48.00% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
150,262.00
143,191.00
4.94%
Operating Profit (PBDIT) excl Other Income
19,544.00
17,081.00
14.42%
Interest
119.00
118.00
0.85%
Exceptional Items
-227.00
-10.00
-2,170.00%
Consolidate Net Profit
8,009.00
6,509.00
23.05%
Operating Profit Margin (Excl OI)
69.40%
65.40%
0.40%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 4.94% vs 3.79% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 23.05% vs 3.93% in Mar 2025
About BML, Inc. 
BML, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






